JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

25.29 -0.51

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.41

Максимум

25.54

Ключови измерители

By Trading Economics

Приходи

7.7M

-41M

Продажби

3.5M

110M

Марж на печалбата

-37.032

Служители

1,869

EBITDA

1.4M

-55M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+118.93% upside

Дивиденти

By Dow Jones

Следващи печалби

6.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-1.2B

3B

Предишно отваряне

25.8

Предишно затваряне

25.29

Настроения в новините

By Acuity

100%

0%

358 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.10.2025 г., 23:28 ч. UTC

Горещи акции

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29.10.2025 г., 23:07 ч. UTC

Печалби

Prudential PLC 3Q New Business Profit Up 13%

30.10.2025 г., 00:00 ч. UTC

Печалби

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30.10.2025 г., 00:00 ч. UTC

Печалби

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30.10.2025 г., 00:00 ч. UTC

Печалби

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29.10.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29.10.2025 г., 23:40 ч. UTC

Печалби

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29.10.2025 г., 23:38 ч. UTC

Пазарно говорене

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29.10.2025 г., 23:25 ч. UTC

Печалби

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29.10.2025 г., 22:51 ч. UTC

Печалби

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29.10.2025 г., 22:45 ч. UTC

Печалби

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29.10.2025 г., 22:41 ч. UTC

Печалби

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29.10.2025 г., 22:41 ч. UTC

Печалби

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29.10.2025 г., 22:09 ч. UTC

Печалби

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29.10.2025 г., 22:08 ч. UTC

Пазарно говорене
Печалби

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29.10.2025 г., 21:58 ч. UTC

Печалби

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29.10.2025 г., 21:58 ч. UTC

Печалби

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29.10.2025 г., 21:57 ч. UTC

Печалби

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29.10.2025 г., 21:54 ч. UTC

Печалби

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29.10.2025 г., 21:46 ч. UTC

Печалби

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29.10.2025 г., 21:43 ч. UTC

Печалби

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29.10.2025 г., 21:43 ч. UTC

Печалби

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29.10.2025 г., 21:42 ч. UTC

Печалби

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29.10.2025 г., 21:42 ч. UTC

Печалби

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29.10.2025 г., 21:41 ч. UTC

Печалби

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29.10.2025 г., 21:41 ч. UTC

Печалби

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29.10.2025 г., 21:41 ч. UTC

Печалби

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29.10.2025 г., 21:41 ч. UTC

Печалби

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29.10.2025 г., 21:40 ч. UTC

Печалби

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29.10.2025 г., 21:39 ч. UTC

Печалби

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

118.93% нагоре

12-месечна прогноза

Среден 55.63 USD  118.93%

Висок 74 USD

Нисък 39 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

6

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat